Hello everyone,
Today I want to address an issue that affects millions of people around the world: type 2 diabetes and the complex business that is hidden behind insulin treatment.This issue is not only a matter of public health, but also a huge business that seems to prioritize economic benefits on the well -being of patients.
For decades, type 2 diabetes has been subject to multiple debates.While it is true that this metabolic disease can be controlled and even reversed with strict low carbohydrate diets, the reality is that these solutions are not always properly promoted.
Because?The answer seems to be in the economic interests of the pharmaceutical and food industry.
In the United States, more than 100,000 people die annually due to diabetes, and the costs associated with their treatment amount to about 400,000 million dollars a year.
Although type 2 diabetes is reversible, the American Diabetes Association (ADA) continues to promote conventional treatments that include insulin use.This is particularly controversial, since numerous investigations have shown that a low carbohydrate diet can be effective to reverse this condition without the need for medication.
However, it seems that there is a dark framework that benefits from keeping patients dependent on expensive and often unnecessary medicines.The financial contributions of the pharmaceutical industry to organizations such as the ADA have been significant, which raises questions about the impartiality of treatment recommendations.
Elizabeth Hanna, a nutritionist who was fired by the ADA for refusing to approve recipes containing high amounts of Splenda, is just an example of how economic interests can influence health practices.This sweetener, although donated by an important company, has been linked to health problems such as glucose intolerance.
The history of insulin is also revealing.Since its discovery in 1921, insulin has been seen as a business opportunity for pharmacists, although the patent was originally sold for only 1 dollar to facilitate its distribution.Today, companies that control insulin production and distribution enjoy millionaire income, while millions of patients fight with treatment costs.
As a society we must demand more transparency and a more patient -centered approach that is not only limited to pharmacological treatment, but also includes changes in lifestyle, such as the adoption of healthy diets.It is time for us to prioritize the health and well -being of people over the economic benefits of a few companies.
This issue is of the utmost importance and must be discussed openly.Health and prevention education are essential to address this epidemic effectively.We must be informed and be critical of the information we receive, and always seek the best interest to our health and that of our loved ones.
Thank you for taking the time to read and reflect on this subject.Together we can make a difference.
Greetings,
